J&

Johnson & Johnson

Every trial this sponsor leads in the registry, and everything it has published.

2,936All trials
Recruiting108
Recruited122
Not yet recruiting10
By invitation2
Completed2,325
Stopped361
Other8

242 active · 8% of this sponsor’s registry footprint

Oncology120 trials
Immunology & Inflammation26 trials
Cardiovascular24 trials
Psychiatry & Addiction14 trials
Pain & Musculoskeletal13 trials
Dermatology11 trials
Neurology8 trials
Ophthalmology6 trials

Not shown above: 1 Phase 1 healthy-volunteer trial and 10 trials whose condition matched no therapy area.

Trials by phase

Phase 1928
Phase 2525
Phase 3806
Phase 4272
Unphased405

Pipeline by phase · 60 drugs in active development

Phase 3 · 28 drugs

Amivantamab13 trials · 9 recruitingest. Dec 2026
Nipocalimab (M281)12 trials · 9 recruitingest. Feb 2027
Icotrokinra (JNJ-77242113)10 trials · 3 recruitingest. Feb 2027
Apalutamide (JNJ 56021927)9 trialsest. Oct 2026
Talquetamab8 trials · 2 recruitingest. Jun 2027
Erdafitinib (TAR-210)7 trials · 2 recruitingest. Mar 2028
Pasritamig (JNJ-78278343)7 trials · 6 recruitingest. Jan 2027
Ramantamig (JNJ-79635322)7 trials · 6 recruitingest. Apr 2027

Phase 2 · 6 drugs

JNJ-955975282 trialsest. Nov 2026
Bedaquiline1 trial · 1 recruitingest. Feb 2027
JNJ-640420561 trialest. Dec 2026
JNJ-812018871 trial · 1 recruitingest. Aug 2029
JNJ-885452231 trial · 1 recruitingest. Jun 2027
Rilpivirine1 trial

Phase 1 · 24 drugs

JNJ-809485432 trials
Abiraterone1 trial
Ami-LC-MD1 trial
ARX5171 trialest. Dec 2026
Aticaprant1 trial · 1 recruitingest. Jun 2027
Capmatinib1 trialest. Apr 2027
HLD-01171 trial · 1 recruitingest. Apr 2028
HLD-0915 Hard Capsule1 trial · 1 recruitingest. Jul 2028

Phase 4 · 2 drugs

Guselkumab18 trials · 5 recruitingest. Feb 2027
Ciltacabtagene Autoleucel (JNJ-68284528)6 trials · 2 recruitingest. Feb 2027

Not counted above: 2 combination backbones (established drugs used alongside the assets).

Active trials only, code names and brands merged. 2,325 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 6 of 10 curated

Multiple myeloma (Oncology)29 trials · 12 recruiting · 7 drugs3.7% of landscape
Non-small cell lung cancer (Oncology)16 trials · 5 recruiting · 5 drugs1.1% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)8 trials · 3 recruiting · 4 drugs4.7% of landscape
Alzheimer's disease (Neurology)2 trials · 1 recruiting · 1 drug0.5% of landscape
Atopic dermatitis (Dermatology)1 trial · 1 drug0.6% of landscape
Breast cancer (Oncology)1 trial · 1 recruiting · 1 drug<0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon